About this Medicine article
Chimeric Antigen Receptor Design Today and Tomorrow by Justin C. Boucher; Marco L. Davila is a Medicine article available to read on EtoBox.
The US Food and Drug Administration has approved 3 chimeric antigen receptor (CAR) T-cell therapies. For continued breakthroughs, novel CAR designs are needed. This includes different antigen-binding domains such as antigen-ligand binding partners and variable lymphocyte receptors. Another recent advancement in CAR design is Boolean logic gates that can minimize on-target, off-tumor toxicities. Recent studies on the optimization of costimulatory signaling have also shown how CAR design can impact function. By using specific signaling pathways and transcription factors, CARs can impact T-cell gene expression to enhance function. By using these techniques, the promise of CAR T-cell therapies for solid tumors can be fulfilled.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Justin C. Boucher; Marco L. Davila
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Published
- 2021
- Language
- EN
- Field
- Medicine (Health Sciences)